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Abstract
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function mutations were first
described in 2003. The gain-of-function mutations observed were associated with low-density lipoprotein-
cholesterol (LDL-C) levels in the 400’s, in addition to premature cardiovascular disease. Subsequent loss-of-
function experiments conducted in mice demonstrated marked reductions in plasma cholesterol levels in the
absence of PCSK9. Physiologically, PCSK9 serves as a chaperone protein and functions to reduce low-density
lipoprotein (LDL) receptor recycling; consequently, less LDL-C is removed from circulation and serum lipid
concentrations become elevated. Inhibition of PCSK9 prevents LDL receptor degradation and preserves
receptor recycling to the hepatocyte surface; this in turn results in reduced LDL-C levels. We report a lack of
cross-sensitivity following the administration of evolocumab after an allergic reaction to alirocumab.
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Abstract 
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function mutations were 
first described in 2003. The gain-of-function mutations observed were associated with low-density 
lipoprotein-cholesterol (LDL-C) levels in the 400’s, in addition to premature cardiovascular disease. 
Subsequent loss-of-function experiments conducted in mice demonstrated marked reductions in plasma 
cholesterol levels in the absence of PCSK9. Physiologically, PCSK9 serves as a chaperone protein and 
functions to reduce low-density lipoprotein (LDL) receptor recycling; consequently, less LDL-C is 
removed from circulation and serum lipid concentrations become elevated. Inhibition of PCSK9 delays 
LDL receptor degradation and preserves receptor recycling to the hepatocyte surface; this in turn results 
in reduced LDL-C levels. Clinical studies have demonstrated consistent reductions in LDL-C of 50% to 
60%. We report a lack of cross-reactivity following the administration of evolocumab after an allergic 
reaction to alirocumab. 
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Introduction 
Two PCSK9 inhibitors, alirocumab and 
evolocumab, have been commercially available in the 
United States since the summer of 2015 and each has 
demonstrated appreciable and consistent reductions in 
LDL-C levels. Both agents are indicated as an adjunct to 
diet for patients on maximally tolerated statin therapy 
with clinical atherosclerotic cardiovascular disease or 
heterozygous familial hypercholesterolemia who require 
additional LDL-C lowering.1,2  In addition, evolocumab is 
indicated for homozygous familial 
hypercholesterolemia.2 Although prospective 
cardiovascular outcome studies are currently ongoing, a 
recent meta-analysis reported a significant decrease in all-
cause mortality (odds ratio [OR] 0.45; 95% confidence 
interval [95% CI] 0.23 to 0.86; p = 0.015) and a non-
significant decrease in cardiovascular mortality (OR 0.50; 
95% CI 0.23 to 1.10; p = 0.084).3 The most common 
reported adverse reactions for alirocumab include: 
nasopharyngitis, injection site reactions and influenza. 1  
In addition to the adverse reactions associated with 
alirocumab, influenza, upper respiratory tract infections 
and back pain are cited as common adverse reactions for 
evolocumab.2 
Case Report 
We report a case of a 63-year-old female who was 
initiated on alirocumab 75 mg, the recommended starting 
dose,1 once every 2 weeks for the management of her 
dyslipidemia. Her past medical history is remarkable for 
coronary calcifications, peripheral vascular disease, 
including carotid plaque, likely heterozygous familial 
hypercholesterolemia, hypertension, dyslipidemia, 
anemia, obesity, status-post Roux-en-Y gastric bypass 
surgery, ischemic colitis, which was associated with a 
gastrointestinal bleed, osteopenia and drop attacks 
causing a fractured shoulder. She also has a significant 
family history for premature heart disease as her brother 
died from a myocardial infarction (MI) at 50 years of age, 
her father died from an MI at age 46 and her mother 
experienced an MI and stroke at age 60. At the time of 
referral, the patient was receiving moderate-intensity 
statin therapy, rosuvastatin 5 mg once daily, with an LDL-
C level of 135 mg/dL. Additional medications the patient 
was taking concurrently, which remained unchanged for 
over a year, included: hydrochlorothiazide 25 mg once 
daily, lisinopril 20 mg twice daily, omeprazole delayed 
release 40 mg twice daily, sucralfate 1 g / 10 mL two 
teaspoonfuls four times daily, CoQ10 once daily and a 
multivitamin once daily. 
Following the administration of the first dose of 
alirocumab, the patient described a low-grade rash that 
spread from her torso to her arms, which resolved after 1 
week. Two weeks later she self-administered her second 
dose of alirocumab and a more severe rash developed on 
her torso. Since this patient is at high risk for 
cardiovascular events, a mutual and informed decision 
was made to switch her to evolocumab. To the best of our 
knowledge, there are currently no published case reports 
describing an allergic reaction to one PCSK9 inhibitor 
and a subsequent challenge with the alternative agent. 
Sixteen days after her last dose of alirocumab, the 
patient self-administered her first dose of evolocumab 140 
mg, a recommended starting dose,2 at our outpatient 
practice. In the abundance of caution, the patient received 
diphenhydramine prophylactically and remained under 
close supervision for thirty minutes with epinephrine 
nearby. After 10 months of biweekly evolocumab 
injections, this patient has not received any additional 
prophylactic diphenhydramine nor has she manifested 
any symptoms of an allergic reaction. Her cholesterol 
continues to remain significantly improved from baseline. 
The patient’s history of lipid results is presented in Tables 
1 and 2. 
 
Dates 
 
TC  
(mg/ dL) 
LDL- C  
(mg/ dL) 
HDL- C  
(mg/ dL) 
Non- 
HDL- C  
(mg/dL) 
 
TG 
(mg/ dL) 
Baseline 
9/18/2015 243 135 81 162 134 
Alirocumab 
[Initiated: 9/21/2015, last dose received 10/05/2015] 
10/20/2015 160 34 104 56 114 
Switch to Evolocumab 
[Initiated: 10/21/2015] 
11/17/2015 129 28 86 43 75 
Abbreviations: HDL-C – high-density lipoprotein 
cholesterol; LDL-C – low-density lipoprotein cholesterol; 
non-HDL-C – non-high-density lipoprotein cholesterol; TC 
– total cholesterol; TG – triglycerides 
Table 1: Baseline and follow-up lipid laboratory 
information after the initiation of both PCSK9 inhibitors. 
 
One reason that may explain the lack of 
immunogenicity observed following a challenge with the 
second PCSK9 inhibitor is the difference in the inactive 
ingredients of each product. The inactive ingredients in 
alirocumab include: histidine, polysorbate 20, sucrose and 
water for injection,1 while the inactive ingredients for 
evolocumab include acetate, polysorbate 80, proline, 
water for injection and    sodium hydroxide2. According 
to the prescribing information, hypersensitivity reactions, 
including serious events (e.g., hypersensitivity vasculitis 
and hypersensitivity reactions requiring hospitalization) 
have been reported with alirocumab; allergic reactions 
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were reported in 8.6% of patients receiving alirocumab 
and 7.8% of patients receiving placebo, with 0.6% and 
0.2%, respectively, discontinuing treatment because of 
an allergic reaction.1 Allergic reactions occurred in 5.1% 
of patients receiving evolocumab compared to 4.7% of 
patients receiving placebo.2 Although it is not listed in 
the prescribing information, a personal communication 
with  the  manufacturer  of  evolocumab  described    one 
patient who reported a hypersensitivity reaction and 
subsequently discontinued evolocumab therapy. 
Certain drug information resources (e.g., 
Lexicomp®) discourage the use of an alternative PCSK9 
inhibitor when an allergic reaction occurs, because of 
similarities in structures.4 However, this is not an absolute 
contraindication, nor is it stated in the package insert for 
either agent.1,2 
This case reports the successful use of an 
alternative PCSK9 inhibitor in a patient with a 
documented allergic reaction to initial PCSK9 inhibitor 
therapy. 
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PCSK9 
Inhibitor 
Percent Reduction in Lipid Values 
from Baseline 
TC  LDL-C  HDL-C  
Non-
HDL-C  
TG 
Alirocumab 
Compared 
to Baseline 
(%) 
 
-34.2 
 
-74.8 
 
+28.4 
 
-65.4 
 
-14.9 
Evolocumab 
Compared 
to Baseline 
(%) 
 
-46.9 
 
-79.3 
 
+6.2 
 
-73.5 
 
-44.0 
Evolocumab 
Compared 
to 
Alirocumab 
(%) 
 
 
-19.4 
 
 
-17.6 
 
 
-17.3 
 
 
-23.2 
 
 
-34.2 
Abbre via tio n s: HDL -C – high-d e nsi ty lipop ro tein 
chole ste r ol ; LDL -C – low-d e nsi ty lipopro tein chole ste r ol ; 
non-H D L - C – non-hig h- de n si ty lipopr ote in chole ste rol ; 
PCSK 9 - propro tein conv er tas e subti l i s in/ke x in type 9; TC – 
total choleste ro l; TG – triglyc e rid e s 
 Table 2: Percent change in lipids compared to 
baseline for each PCSK9 inhibitor and the 
percent change in lipids following the switch to 
evolocumab compared to alirocumab. 
